Sivik Global Healthcare Llc decreased Aetna Inc New Com Stk (AET) stake by 18.03% reported in 2017Q2 SEC filing. Sivik Global Healthcare Llc sold 9,900 shares as Aetna Inc New Com Stk (AET)’s stock rose 12.84%. The Sivik Global Healthcare Llc holds 45,000 shares with $6.83 million value, down from 54,900 last quarter. Aetna Inc New Com Stk now has $58.24B valuation. The stock decreased 0.17% or $0.3 during the last trading session, reaching $178.6. About 2.98M shares traded or 3.44% up from the average. Aetna Inc. (NYSE:AET) has risen 28.84% since December 7, 2016 and is uptrending. It has outperformed by 12.14% the S&P500.
Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics has $145.0 highest and $18 lowest target. $96.67’s average target is -39.17% below currents $158.9125 stock price. SAGE Therapeutics had 44 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, October 26. The rating was maintained by Needham on Tuesday, June 13 with “Buy”. BMO Capital Markets maintained the shares of SAGE in report on Thursday, August 3 with “Buy” rating. The stock has “Buy” rating by Cowen & Co on Tuesday, September 12. The stock has “Buy” rating by Leerink Swann on Tuesday, September 12. H.C. Wainwright initiated it with “Buy” rating and $56 target in Thursday, June 23 report. As per Thursday, November 9, the company rating was maintained by RBC Capital Markets. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, August 3 by Cowen & Co. RBC Capital Markets maintained the shares of SAGE in report on Thursday, November 2 with “Buy” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Monday, November 14 by Stifel Nicolaus.
Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on February, 22. They expect $-2.00 earnings per share, down 33.33% or $0.50 from last year’s $-1.5 per share. After $-1.97 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.52% negative EPS growth.
The stock increased 72.92% or $67.0125 during the last trading session, reaching $158.9125. About 6.82 million shares traded or 701.56% up from the average. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since December 7, 2016 and is uptrending. It has outperformed by 99.75% the S&P500.
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $6.52 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.
Investors sentiment decreased to 0.98 in 2017 Q2. Its down 0.13, from 1.11 in 2017Q1. It turned negative, as 24 investors sold Sage Therapeutics, Inc. shares while 61 reduced holdings. 30 funds opened positions while 53 raised stakes. 37.20 million shares or 2.18% more from 36.41 million shares in 2017Q1 were reported. Jpmorgan Chase And Com reported 818,671 shares stake. Artal Group stated it has 90,000 shares or 0.13% of all its holdings. Bb Biotech Ag accumulated 907,439 shares or 2.21% of the stock. Bankshares Of Montreal Can holds 0% or 204 shares in its portfolio. Vanguard Group has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Raymond James And Assoc has invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Northwestern Mutual Wealth Commerce holds 34 shares or 0% of its portfolio. Wellington Mngmt Llp, Massachusetts-based fund reported 1.58 million shares. 69,900 are owned by Spark Inv Mgmt Ltd Com. Quantitative Investment Mgmt Ltd Company holds 0.07% or 58,400 shares. Brown Advisory accumulated 3,111 shares or 0% of the stock. Tiaa Cref Invest Lc has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Pioneer Mgmt stated it has 158,418 shares. Lord Abbett & Limited Liability Company holds 0.09% or 361,688 shares. Tradewinds Mngmt Llc stated it has 137 shares.
Among 23 analysts covering Aetna (NYSE:AET), 9 have Buy rating, 0 Sell and 14 Hold. Therefore 39% are positive. Aetna had 61 analyst reports since July 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained Aetna Inc. (NYSE:AET) on Friday, June 9 with “Outperform” rating. Jefferies maintained it with “Hold” rating and $163.0 target in Tuesday, September 5 report. Deutsche Bank maintained Aetna Inc. (NYSE:AET) on Thursday, July 13 with “Hold” rating. Bernstein initiated Aetna Inc. (NYSE:AET) on Thursday, June 16 with “Outperform” rating. The stock has “Market Perform” rating by BMO Capital Markets on Friday, October 27. The firm has “Hold” rating given on Friday, January 8 by Jefferies. Cantor Fitzgerald maintained it with “Hold” rating and $175.0 target in Tuesday, October 31 report. On Friday, October 27 the stock rating was downgraded by Cantor Fitzgerald to “Neutral”. Deutsche Bank maintained it with “Hold” rating and $163 target in Monday, August 7 report. Jefferies maintained Aetna Inc. (NYSE:AET) on Thursday, August 3 with “Hold” rating.
Sivik Global Healthcare Llc increased Molina Healthcare Inc Com Stk (NYSE:MOH) stake by 62,500 shares to 82,500 valued at $5.71 million in 2017Q2. It also upped Intuitive Surgical Inc (NASDAQ:ISRG) stake by 1,000 shares and now owns 3,250 shares. Smith & Nephew Plc Adr (NYSE:SNN) was raised too.
Analysts await Aetna Inc. (NYSE:AET) to report earnings on January, 30. They expect $1.23 EPS, down 24.54% or $0.40 from last year’s $1.63 per share. AET’s profit will be $401.10 million for 36.30 P/E if the $1.23 EPS becomes a reality. After $2.45 actual EPS reported by Aetna Inc. for the previous quarter, Wall Street now forecasts -49.80% negative EPS growth.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.